Skip to main content
SpringerLink
Log in

Chemoprevention

  • Chapter
Multiple Primary Malignancies

Part of the book series: Updates in Surgery ((UPDATESSURG))

  • 665 Accesses

Abstract

Prevention represents an absolutely relevant area of oncology, its aim being to prevent the onset of cancer and to reduce mortality. The goal is to re-balance the factors that promote and inhibit carcinogenesis, including the countless exogenous (environmental) and endogenous (genetic) mechanisms. In the field of prevention, it is possible to distinguish four broad areas of research: primary prevention, secondary prevention, tertiary prevention, and chemoprevention.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. De Vita VT, Hellman S Jr, Rosenberg SA (eds) (2005) Cancer, principles e practise of oncology. 7th edition. Lippincott Raven, Philadelphia

    Google Scholar 

  2. Park SM, Lim MK, Jung KW et al (2007) Prediagnosis smoking, obesity, insulin resistance, and second primary cancer risk in male cancer survivors: National Health Insurance Corporation Study. J Clin Oncol 25:4835–4843

    Article  PubMed  Google Scholar 

  3. Wu X, Zhao H, Do KA et al (2004) Serum levels of insulin growth factor (IGF-I) and IGF-binding protein predict risk of second primary tumors in patients with head and neck cancer. Clin Cancer Res 10:3988–3995

    Article  PubMed  CAS  Google Scholar 

  4. Do KA, Johnson MM, Doherty DA et al (2003) Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). Cancer Causes Control 14(2):131–138

    Article  PubMed  Google Scholar 

  5. Gao X, Fisher SG, Mohideen N, Emami B (2003) Second primary cancers in patients with laryngeal cancer: a population-based study. Int J Radiat Oncol Biol Phis. 56(2):427–435

    Article  Google Scholar 

  6. Minard CG, Spitz MR, Wu X et al (2006) Evaluation of glutathione S-transferase polymorphisms and mutagen sensitivity as risk factors for the development of second primary tumors in patients previously diagnosed with early-stage head and neck cancer. Cancer 106:2636–2644

    Article  PubMed  Google Scholar 

  7. Travis LB, Fosså SD, Schonfeld SJ et al (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97(18):1354–1365

    PubMed  Google Scholar 

  8. Hong WK, Lippman SM, Itri LM et al (1990) Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323(12):795–801

    PubMed  CAS  Google Scholar 

  9. Bolla M, Lefur R, Ton Van J et al (1994) Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicentric double-blind randomised study. Eur J Cancer 30A(6):767–772

    Article  PubMed  CAS  Google Scholar 

  10. van Zandwijk N, Dalesio O, Pastorino U et al (2000) EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. J Natl Cancer Inst 92(12):977–986

    Article  PubMed  Google Scholar 

  11. Mayne ST, Cartmel B, Baum M et al (2001) Randomized trial of supplemental ß-carotene to prevent second head and neck cancer. Cancer Research 61:1457–1463

    PubMed  CAS  Google Scholar 

  12. Bairati I, Meyer F, Gélinas M et al (2005) A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst 97(7):481–488

    PubMed  CAS  Google Scholar 

  13. Khuri FR, Lee JJ, Lippman SM et al (2006) Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 98(7):441–450

    PubMed  CAS  Google Scholar 

  14. Anonymous (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 330(15): 1029–1035

    Article  Google Scholar 

  15. Omenn GS, Goodman GE, Thornquist MD et al (1996) Effects of a combination of betacarotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334(18):1150–1155

    Article  PubMed  CAS  Google Scholar 

  16. Lippman SM, Lee JJ, Karp DD et al (2001) Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 93(8):605–618

    Article  PubMed  CAS  Google Scholar 

  17. Bevers TB (2007) The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women. J Natl Compr Canc Netw 5(8):719–724

    PubMed  Google Scholar 

  18. Veronesi U, Mariani L, Decensi A et al (2006) Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 17:1065–1071

    Article  PubMed  CAS  Google Scholar 

  19. Bertelsen L, Bernstein L, Olsen JH et al (2008) Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the women’s environment, cancer and radiation epidemiology study. J Natl Cancer Inst 100:32–40

    Article  PubMed  CAS  Google Scholar 

  20. Tangrea JA, Edwards BK, Taylor PR et al (1992) Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. J Natl Cancer Inst 84:328–332

    Article  PubMed  CAS  Google Scholar 

  21. Levine N, Moon TE, Cartmel B et al (1997) Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev 6:957–961

    PubMed  CAS  Google Scholar 

  22. Moon TE, Levine N, Cartmel B et al (1997) Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Cancer Epidemiol Biomarkers Prev 6:949–956

    PubMed  CAS  Google Scholar 

  23. Clark LC, Combs GF Jr, Turnbull BW et al (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276:1957–1963

    Article  PubMed  CAS  Google Scholar 

  24. Duffield-Lillico, Slate EH, Reid ME AJ et al (2003) Selenium supplementation and secondary prevention of non melanoma skin cancer in a randomized trial. J Natl Cancer Inst 95:1477–1481

    PubMed  CAS  Google Scholar 

  25. Pedersen H, Wolf H, Jensen SK et al (1984) Administration of a retinoid as prophylaxis of recurrent non-invasive bladder tumors. Scand J Urol Nephrol 18:121–123

    Article  PubMed  CAS  Google Scholar 

  26. Alfthan O, Tarkkanen J, Groehn P et al (1983) Tigason (etretinate) in prevention of recurrence of superficial bladder tumors. Eur Urol 9:6–9

    PubMed  CAS  Google Scholar 

  27. Studer UE, Biedermann C, Chollet D et al (1984) Prevention of recurrent superficial bladder tumors by oral etretinate: preliminary results of a randomized, double blind multicenter trial in Switzerland. J Urol 131:47–49

    PubMed  CAS  Google Scholar 

  28. Cruz-Correa, Hylind LM, Romans KE M et al (2002) Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 122(3): 641–645

    Article  PubMed  CAS  Google Scholar 

  29. Asano TK, McLeod RS (2004) Non steroidal anti-inflammatory drugs (NSAID) and aspirin for preventing colorectal adenomas and carcinomas. Cochrane Database of Systematic Reviews 2004, Issue 1, CD004079. DOI:10.1002/14651858.CD004079.pub2

    Google Scholar 

  30. Sun SY, Hail N Jr, Lotan R (2004) Apoptosis as a novel target for cancer chemoprevention. JNCI 96:662–672

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Surgical, Anesthesiology-rianimative and Emergency Sciences Department, Federico II University, Naples, Italy

    Pietro Lombari

  2. Medical Oncology, Department of Clinical and Experimental Medicine “F. Magrassi - A. Lanzara”, Second University of Naples, Naples, Italy

    Gaetano Aurilio, Fernando De Vita & Giuseppe Catalano

Authors
  1. Pietro Lombari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gaetano Aurilio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fernando De Vita
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giuseppe Catalano
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag Italia

About this chapter

Cite this chapter

Lombari, P., Aurilio, G., De Vita, F., Catalano, G. (2009). Chemoprevention. In: Multiple Primary Malignancies. Updates in Surgery. Springer, Milano. https://doi.org/10.1007/978-88-470-1095-6_18

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-1095-6_18

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-1094-9

  • Online ISBN: 978-88-470-1095-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation